Ultragenyx Pharmaceutical (RARE) Long-Term Investments (2015 - 2026)

Ultragenyx Pharmaceutical (RARE) has 12 years of Long-Term Investments data on file, last reported at $121.0 million in Q1 2026.

• Quarterly Long-Term Investments rose 76.48% year-over-year to $121.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $121.0 million (up 76.48% YoY) and the FY2025 annual result came in at $57.0 million, down 57.78% from the prior year.
• Long-Term Investments grew to $121.0 million in Q1 2026 per RARE's latest filing, from $57.0 million in the prior quarter.
• Across five years, Long-Term Investments topped out at $215.5 million in Q1 2022 and bottomed at $2.8 million in Q4 2022.
• The 5-year median for Long-Term Investments is $85.2 million (2023), against an average of $97.1 million.
• The widest annual swing landed in 2024, when Long-Term Investments jumped 4113.48%; it then slumped 89.13% in 2025.
• Tracing RARE's Long-Term Investments over 5 years: stood at $2.8 million in 2022, then advanced by 14.14% to $3.2 million in 2023, then jumped by 4113.48% to $135.0 million in 2024, then tumbled by 57.78% to $57.0 million in 2025, then jumped by 112.28% to $121.0 million in 2026.
• Per Business Quant, the three latest RARE Long-Term Investments figures stand at $121.0 million (Q1 2026), $57.0 million (Q4 2025), and $22.1 million (Q3 2025).

Peer Comparison